create 1 slide for following text Active disease should be clearly documented to initiate therapy. At least 1 of the following criteria should be met. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia. Cutoff levels of Hb <10 g/dL or platelet counts <100 × 109/L are generally regarded as indication for treatment. However, in some patients, platelet counts <100 × 109/L may remain stable over a long period; this situation does not automatically require therapeutic intervention. Massive (ie, ≥6 cm below the left costal margin) or progressive or symptomatic splenomegaly. Massive nodes (ie, ≥10 cm in longest diameter) or progressive or symptomatic lymphadenopathy. Progressive lymphocytosis with an increase of ≥50% over a 2-month period, or lymphocyte doubling time (LDT) <6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts <30 × 109/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (eg, infections, steroid administration) should be excluded. Autoimmune complications including anemia or thrombocytopenia poorly responsive to corticosteroids. Symptomatic or functional extranodal involvement (eg, skin, kidney, lung, spine). Disease-related symptoms as defined by any of the following: Unintentional weight loss ≥10% within the previous 6 months. Significant fatigue (ie, ECOG performance scale 2 or worse; cannot work or unable to perform usual activities). Fevers ≥100.5°F or 38.0°C for 2 or more weeks without evidence of infection. Night sweats for ≥1 month without evidence of infection.
create 1 slide for following text
Active disease should be clearly documented to initiate therapy. At least 1 of the following criteria should be met.
Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia. Cutoff levels of Hb <10 g/dL or platelet counts <100 × 109/L are generally regarded as indication for treatment. However, in some patients, platelet counts <100 × 109/L may remain stable over a long period; this situation does not automatically require therapeutic intervention.
Massive (ie, ≥6 cm below the left costal margin) or progressive or symptomatic splenomegaly.
Massive nodes (ie, ≥10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
Progressive lymphocytosis with an increase of ≥50% over a 2-month period, or lymphocyte doubling time (LDT) <6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts <30 × 109/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (eg, infections, steroid administration) should be excluded.
Autoimmune complications including anemia or thrombocytopenia poorly responsive to corticosteroids.
Symptomatic or functional extranodal involvement (eg, skin, kidney, lung, spine).
Disease-related symptoms as defined by any of the following:
Unintentional weight loss ≥10% within the previous 6 months.
Significant fatigue (ie, ECOG performance scale 2 or worse; cannot work or unable to perform usual activities).
Fevers ≥100.5°F or 38.0°C for 2 or more weeks without evidence of infection.
Night sweats for ≥1 month without evidence of infection.
Created using ChatSlide
This guide outlines key considerations for initiating therapy in patients with active, progressive disease. It emphasises the importance of meeting treatment criteria and interpreting clinical thresholds. Core evidence of disease progression includes marrow failure indicators, symptomatic splenomegaly, and significant lymphocytosis. Additionally, it highlights the need for clinical action in response to symptoms such as steroid-refractory autoimmune cytopenias, extranodal involvement, and...